Cargando…
Comparison of the Rate of Posterior Capsule Opacification Following Combined Treatment With Topical Dexamethasone 0.1% Plus Ketorolac 0.5% Eye Drops Versus Dexamethasone 0.1% Alone: A Two-Year, Randomized Clinical Investigation
Background and aim The use of non-steroidal anti-inflammatory drugs in animals decreases the incidence of posterior capsular opacification (PCO) following cataract surgery. We evaluated the rate of PCO in patients with cataract surgery and foldable “in the bag” posterior chamber intraocular lens (PC...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163951/ https://www.ncbi.nlm.nih.gov/pubmed/37159777 http://dx.doi.org/10.7759/cureus.37223 |
_version_ | 1785037988465475584 |
---|---|
author | Evereklioglu, Cem Arda, Hatice Sener, Hidayet Polat, Osman A Gumus, Koray Horozoglu, Fatih |
author_facet | Evereklioglu, Cem Arda, Hatice Sener, Hidayet Polat, Osman A Gumus, Koray Horozoglu, Fatih |
author_sort | Evereklioglu, Cem |
collection | PubMed |
description | Background and aim The use of non-steroidal anti-inflammatory drugs in animals decreases the incidence of posterior capsular opacification (PCO) following cataract surgery. We evaluated the rate of PCO in patients with cataract surgery and foldable “in the bag” posterior chamber intraocular lens (PC-IOL) implantation treated with combined dexamethasone 0.1% plus ketorolac tromethamine 0.5% versus dexamethasone 0.1% alone. Materials and methods A total of 114 eyes of 101 patients underwent uneventful corneal small-incision phacoemulsification with primary implantation of a foldable acrylic PC-IOL (AcrySof(®), Alcon, Fort Worth, USA). Postoperatively for four weeks, group 1 eyes were treated with dexamethasone 0.1% plus ketorolac tromethamine 0.5% ophthalmic solutions four times daily for each whereas group 2 eyes were treated with dexamethasone 0.1% alone. Other regiments were the same for each group. Patients were evaluated between one- and four-year following surgery. The frequency and timing of severe PCO following surgery that needed Nd:YAG laser posterior capsulotomy were recorded and evaluated. Results The mean (SEM) age of group 1 (n = 54) and group 2 (n = 60) at operation was similar (62.8 ± 2.2 vs. 60.6 ± 1.7 years, respectively). Eighty-eight patients had unilateral cataract and 13 cases had bilateral disease. Overall, the mean follow-up duration was 24.7 months postoperatively (range, 15-48). Clinically significant PCO that finally needed Nd:YAG laser application developed in two eyes (3.7%) in group 1 and in four eyes (6.6%) in group 2, and the difference was not statistically significant (p>0.05). The mean month at capsulotomy was 26.5 in group 1 and 24.3 months in group 2 eyes (p>0.05). Conclusions Topical instillation of ketorolac ophthalmic solution in the immediate period after phacoemulsification and PC-IOL implantation did not seem to influence the incidence of PCO formation two years after cataract surgery. |
format | Online Article Text |
id | pubmed-10163951 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-101639512023-05-07 Comparison of the Rate of Posterior Capsule Opacification Following Combined Treatment With Topical Dexamethasone 0.1% Plus Ketorolac 0.5% Eye Drops Versus Dexamethasone 0.1% Alone: A Two-Year, Randomized Clinical Investigation Evereklioglu, Cem Arda, Hatice Sener, Hidayet Polat, Osman A Gumus, Koray Horozoglu, Fatih Cureus Ophthalmology Background and aim The use of non-steroidal anti-inflammatory drugs in animals decreases the incidence of posterior capsular opacification (PCO) following cataract surgery. We evaluated the rate of PCO in patients with cataract surgery and foldable “in the bag” posterior chamber intraocular lens (PC-IOL) implantation treated with combined dexamethasone 0.1% plus ketorolac tromethamine 0.5% versus dexamethasone 0.1% alone. Materials and methods A total of 114 eyes of 101 patients underwent uneventful corneal small-incision phacoemulsification with primary implantation of a foldable acrylic PC-IOL (AcrySof(®), Alcon, Fort Worth, USA). Postoperatively for four weeks, group 1 eyes were treated with dexamethasone 0.1% plus ketorolac tromethamine 0.5% ophthalmic solutions four times daily for each whereas group 2 eyes were treated with dexamethasone 0.1% alone. Other regiments were the same for each group. Patients were evaluated between one- and four-year following surgery. The frequency and timing of severe PCO following surgery that needed Nd:YAG laser posterior capsulotomy were recorded and evaluated. Results The mean (SEM) age of group 1 (n = 54) and group 2 (n = 60) at operation was similar (62.8 ± 2.2 vs. 60.6 ± 1.7 years, respectively). Eighty-eight patients had unilateral cataract and 13 cases had bilateral disease. Overall, the mean follow-up duration was 24.7 months postoperatively (range, 15-48). Clinically significant PCO that finally needed Nd:YAG laser application developed in two eyes (3.7%) in group 1 and in four eyes (6.6%) in group 2, and the difference was not statistically significant (p>0.05). The mean month at capsulotomy was 26.5 in group 1 and 24.3 months in group 2 eyes (p>0.05). Conclusions Topical instillation of ketorolac ophthalmic solution in the immediate period after phacoemulsification and PC-IOL implantation did not seem to influence the incidence of PCO formation two years after cataract surgery. Cureus 2023-04-06 /pmc/articles/PMC10163951/ /pubmed/37159777 http://dx.doi.org/10.7759/cureus.37223 Text en Copyright © 2023, Evereklioglu et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Ophthalmology Evereklioglu, Cem Arda, Hatice Sener, Hidayet Polat, Osman A Gumus, Koray Horozoglu, Fatih Comparison of the Rate of Posterior Capsule Opacification Following Combined Treatment With Topical Dexamethasone 0.1% Plus Ketorolac 0.5% Eye Drops Versus Dexamethasone 0.1% Alone: A Two-Year, Randomized Clinical Investigation |
title | Comparison of the Rate of Posterior Capsule Opacification Following Combined Treatment With Topical Dexamethasone 0.1% Plus Ketorolac 0.5% Eye Drops Versus Dexamethasone 0.1% Alone: A Two-Year, Randomized Clinical Investigation |
title_full | Comparison of the Rate of Posterior Capsule Opacification Following Combined Treatment With Topical Dexamethasone 0.1% Plus Ketorolac 0.5% Eye Drops Versus Dexamethasone 0.1% Alone: A Two-Year, Randomized Clinical Investigation |
title_fullStr | Comparison of the Rate of Posterior Capsule Opacification Following Combined Treatment With Topical Dexamethasone 0.1% Plus Ketorolac 0.5% Eye Drops Versus Dexamethasone 0.1% Alone: A Two-Year, Randomized Clinical Investigation |
title_full_unstemmed | Comparison of the Rate of Posterior Capsule Opacification Following Combined Treatment With Topical Dexamethasone 0.1% Plus Ketorolac 0.5% Eye Drops Versus Dexamethasone 0.1% Alone: A Two-Year, Randomized Clinical Investigation |
title_short | Comparison of the Rate of Posterior Capsule Opacification Following Combined Treatment With Topical Dexamethasone 0.1% Plus Ketorolac 0.5% Eye Drops Versus Dexamethasone 0.1% Alone: A Two-Year, Randomized Clinical Investigation |
title_sort | comparison of the rate of posterior capsule opacification following combined treatment with topical dexamethasone 0.1% plus ketorolac 0.5% eye drops versus dexamethasone 0.1% alone: a two-year, randomized clinical investigation |
topic | Ophthalmology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163951/ https://www.ncbi.nlm.nih.gov/pubmed/37159777 http://dx.doi.org/10.7759/cureus.37223 |
work_keys_str_mv | AT evereklioglucem comparisonoftherateofposteriorcapsuleopacificationfollowingcombinedtreatmentwithtopicaldexamethasone01plusketorolac05eyedropsversusdexamethasone01aloneatwoyearrandomizedclinicalinvestigation AT ardahatice comparisonoftherateofposteriorcapsuleopacificationfollowingcombinedtreatmentwithtopicaldexamethasone01plusketorolac05eyedropsversusdexamethasone01aloneatwoyearrandomizedclinicalinvestigation AT senerhidayet comparisonoftherateofposteriorcapsuleopacificationfollowingcombinedtreatmentwithtopicaldexamethasone01plusketorolac05eyedropsversusdexamethasone01aloneatwoyearrandomizedclinicalinvestigation AT polatosmana comparisonoftherateofposteriorcapsuleopacificationfollowingcombinedtreatmentwithtopicaldexamethasone01plusketorolac05eyedropsversusdexamethasone01aloneatwoyearrandomizedclinicalinvestigation AT gumuskoray comparisonoftherateofposteriorcapsuleopacificationfollowingcombinedtreatmentwithtopicaldexamethasone01plusketorolac05eyedropsversusdexamethasone01aloneatwoyearrandomizedclinicalinvestigation AT horozoglufatih comparisonoftherateofposteriorcapsuleopacificationfollowingcombinedtreatmentwithtopicaldexamethasone01plusketorolac05eyedropsversusdexamethasone01aloneatwoyearrandomizedclinicalinvestigation |